AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03266432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: three blood samples : first one pre intervention and the other two blood samples post-intervention
Study NCT02132039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-step sitting Tai Chi Chuan
Description: The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
Study NCT02132039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
Study NCT00650169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Bisulfate Tablets 75 mg
Description: 75mg, single dose fed
Study NCT00650169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® Tablets 75 mg
Description: 75mg, single dose fed
Study NCT03830320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Study NCT03437811 — intervention group
Intervention type: DEVICE
Intervention: Electro Flo Percussor, Model 5000
Description: FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
Study NCT03715036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care US
Description: The intervention includes reassuring the AC and DVP
Study NCT02053649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple Chronotherapy
Description: triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
Study NCT02053649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
Study NCT02053649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
Study NCT02367690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Topical gel
Study NCT02367690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Surgical debridement, sterile saline rinses, and dressing changes.
Study NCT02367690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle Gel
Description: Topical vehicle gel with no active ingredients.
Study NCT03523390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
Study NCT03523390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
Study NCT03523390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
Study NCT03523390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg QW
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
Study NCT02527291 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood test for CMV PCR and IL28
Study NCT03914924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.
Study NCT03914924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.
Study NCT03914924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.
Study NCT02967042 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 18F-PET-TT
Description: can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
Study NCT02948452 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: fMRI: reward task, anxiety provocation
Study NCT03373006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axumin PET/CT
Description: Synthetic amino acid uptake agent injection followed by imaging
Study NCT03775473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: progastrin
Description: PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: proton pump inhibitor
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: proton pump inhibitor
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: antibiotic for H. pylori eradication
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic for H. pylori eradication
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic for H. pylori eradication
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication
Study NCT02935010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic for H. pylori eradication
Study NCT02026193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte vitrification
Study NCT02026193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo freezing
Study NCT02565303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervertebral space
Study NCT02565303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
Study NCT04602923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: OPD-Scan
Description: Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
Study NCT03830320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Study NCT04602923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal topography: Pentacam
Description: Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
Study NCT03830320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner
Study NCT00514462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: wavelength at 830nm, 9.7J/cm2 for 10 min
Study NCT00444067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Sealant
Description: Spinal Sealant System
Study NCT00444067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT02461082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Expiratory muscle strength training (EMST)
Description: The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
Study NCT02461082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
Study NCT02626390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequent instructions/feedback and an Internal Focus of Attention
Study NCT02626390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal instructions/feedback and an External Focus of Attention
Study NCT06149377 — intervention group
Intervention type: PROCEDURE
Intervention: Test cohort
Study NCT01438177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Study NCT01438177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01438177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Study NCT04546347 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)
Description: Dose of \[14C\]AZD9833 Solution for Infusion
Study NCT01143194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
Study NCT01143194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
Study NCT01143194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oréVida™
Description: 1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
Study NCT01143194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of placebo twice a day
Study NCT02839694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine (DAC)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study NCT02839694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine (DAC)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study NCT02839694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study NCT02839694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrouridine (THU)
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study NCT03830320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET/MR
Description: Whole body imaging using Siemens mMR PET/MR scanner
Study NCT02839694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 400 mg orally twice a day every day for while on DAC-THU therapy
Study NCT04506203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air test
Description: Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
Study NCT03989323 — intervention group
Intervention type: OTHER
Intervention: Estimation of the incidence of the irAE
Description: Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
Study NCT04123613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
Study NCT04546347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet A Dose 1
Description: Dose 1 AZD9833 film-coated tablet A Dose 1
Study NCT04546347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 Oral Solution
Description: AZD9833 Oral Solution
Study NCT04546347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet B Dose 1
Description: AZD9833 film-coated tablet B Dose 1
Study NCT04546347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet A Dose 2
Description: Dose 1 of AZD9833 film-coated tablet A Dose 2
Study NCT04546347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 film-coated tablet B Dose 2
Description: Dose 1 of film-coated tablet B Dose 2
Study NCT04508842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22-Dual-STAR-T
Description: Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
Study NCT00109395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study NCT00109395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study NCT00109395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam CI
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Study NCT02976974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
Study NCT02976974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: * Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension
Study NCT00851799 — intervention group
Intervention type: DRUG
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC
Study NCT00851799 — intervention group
Intervention type: DRUG
Intervention: Ritonavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV
Study NCT00851799 — intervention group
Intervention type: DRUG
Intervention: Atazanavir
Description: 300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV
Study NCT00851799 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: 400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL
Study NCT00851799 — intervention group
Intervention type: DRUG
Intervention: Darunavir
Description: 100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV
Study NCT05948202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
Study NCT05948202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Treatment
Description: Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
Study NCT02196272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led reminder program through email
Description: Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form.
Study NCT04574804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training program in weight management for osteoarthritis
Description: An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention.
Study NCT00451867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Study NCT00364351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet
Study NCT00451867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycofenolate Mofetil (MMF)
Description: 2000 mg per day divided into 2 equal doses.
Study NCT00451867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01749579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
Study NCT01749579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
Study NCT03830320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Collection
Description: A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry